Screening of Critical Genes in Lung Adenocarcinoma via Network Analysis of Gene Expression Profile

Pathology and Oncology Research

Volumn 20, Issue 4, 2014, Pages 853-858

  Huang, Ping ^a   Cao, Kejian ^a   Zhao, Heng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Differentially expressed gene; Functional enrichment analysis; Gene expression core signature; Gene expression profile; Lung adenocarcinoma; Network clustering

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; COMPARATIVE STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; HUMAN; LUNG; LUNG TUMOR; METABOLISM;

ADENOCARCINOMA; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; LUNG; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84936143244     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9764-z     Document Type: Article

References (33)

1. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A (2010) Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 36(Suppl 3):S21–29. doi:10.1016/S0305-7372(10)70016-5
2. Gerber DE, Minna JD (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18(6):548–551
3. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367–1380. doi:10.1056/NEJMra0802714
4. Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lung cancer–is it becoming a reality? Nat Rev Clin Oncol 7(7):401–414. doi:10.1038/nrclinonc.2010.64
5. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12(2):175–180. doi:10.1016/S1470-2045(10)70087-5
6. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33(20):e175
7. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249–264. doi:10.1093/biostatistics/4.2.249
8. da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44–57
9. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795):1929–1935
10. Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, Galeota E, Sacco F, Palma A, Nardozza AP, Santonico E, Castagnoli L, Cesareni G (2012) MINT, the molecular interaction database: 2012 update. Nucleic Acids Res 40(Database issue):D857–861. doi:10.1093/nar/gkr930
11. Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, Stark C, Nixon J, Ramage L, Kolas N, O’Donnell L, Reguly T, Breitkreutz A, Sellam A, Chen D, Chang C, Rust J, Livstone M, Oughtred R, Dolinski K, Tyers M (2013) The BioGRID interaction database: 2013 update. Nucleic Acids Res 41(D1):D816–823. doi:10.1093/nar/gks1158
12. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A (2009) Human Protein Reference Database–2009 update. Nucleic Acids Res 37(Database issue):D767–772. doi:10.1093/nar/gkn892
13. Enright AJ, Van Dongen S, Ouzounis CA (2002) An efficient algorithm for large-scale detection of protein families. Nucleic Acids Res 30(7):1575–1584
14. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504
15. Zhang QC, Jiang SJ, Zhang S, Ma XB (2012) Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line. Asian Pac J Cancer Prev 13(7):3471–3476
16. Henry CJ (2010) Biomarkers in veterinary cancer screening: applications, limitations and expectations. Vet J 185(1):10–14
17. Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, Chen Y, Chen QB, Wang YH, He E (2011) Serological thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors 11(12):11064–11080
18. Korkmaz T, Seber S, Okutur K, Basaran G, Yumuk F, Dane F, Ones T, Polat O, Madenci OC, Demir G, Turhal NS (2013) Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers 18(1):88–94. doi:10.3109/1354750X.2012.738250
19. Xu Y, Shi QL, Ma H, Zhou H, Lu Z, Yu B, Zhou X, Eriksson S, He E, Skog S (2012) High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma. Tumour Biol 33(2):475–483. doi:10.1007/s13277-011-0276-0
20. Peng C-Y, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277(5331):1501–1505
21. Krause K, Haugwitz U, Wasner M, Wiedmann M, Mössner J, Engeland K (2001) Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73. Biochem Biophys Res Commun 284(3):743–750
22. Carmazzi Y, Iorio M, Armani C, Cianchetti S, Raggi F, Neri T, Cordazzo C, Petrini S, Vanacore R, Bogazzi F, Paggiaro P, Celi A (2012) The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines. Cell Prolif 45(6):545–556. doi:10.1111/j.1365-2184.2012.00847.x
23. Li QQ, Wang G, Huang F, Li JM, Cuff CF, Reed E (2013) Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of beta-elemene and its synthetic analogs. Med Oncol 30(1):488. doi:10.1007/s12032-013-0488-9
24. van Belzen N, Diesveld MP, van der Made AC, Nozawa Y, Dinjens WN, Vlietstra R, Trapman J, Bosman FT (1995) Identification of mRNAs that show modulated expression during colon carcinoma cell differentiation. Eur J Biochem 234(3):843–848
25. van Belzen N, Dinjens WN, Eussen BH, Bosman FT (1998) Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol Histopathol 13(4):1233–1242
26. Handa Y, Hikawa Y, Tochio N, Kogure H, Inoue M, Koshiba S, Guntert P, Inoue Y, Kigawa T, Yokoyama S, Nameki N (2010) Solution structure of the catalytic domain of the mitochondrial protein ICT1 that is essential for cell vitality. J Mol Biol 404(2):260–273. doi:10.1016/j.jmb.2010.09.033
27. Richter R, Rorbach J, Pajak A, Smith PM, Wessels HJ, Huynen MA, Smeitink JA, Lightowlers RN, Chrzanowska-Lightowlers ZM (2010) A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human mitochondrial ribosome. EMBO J 29(6):1116–1125. doi:10.1038/emboj.2010.14
28. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2):268–273
29. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100(20):11606–11611
30. Weikert S, Christoph F, Köllermann J, Müller M, Schrader M, Miller K, Krause H (2005) Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16(2):349
31. Cao W, Ribeiro Rde O, Liu D, Saintigny P, Xia R, Xue Y, Lin R, Mao L, Ren H (2012) EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One 7(12):e52984
32. Lin YW, Ren LL, Xiong H, Du W, Yu YN, Sun TT, Weng YR, Wang ZH, Wang JL, Wang YC, Cui Y, Sun DF, Han ZG, Shen N, Zou WP, Xu J, Chen HY, Cao WB, Hong J, Fang JY (2013) Role of STAT3 and Vitamin D Receptor in EZH2-mediated invasion of human colorectal cancer. J Pathol. doi:10.1002/path.4179
33. Zhang J-G, Guo J-F, Liu D-L, Liu Q, Wang J-J (2011) MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 6(4):671–678